The New York Times reports that Chantix was linked to an increased risk of heart attacks, strokes or other serious cardiovascular problems. The article included statements from Pfizer and the author of the report published in the Canadian Meical Association Journal.
Pfizer, in a statement, said the analysis in the Canadian Medical Association Journal was based on too few heart or cardiovascular events to draw conclusions about the risks. The company said Chantix brought “immediate and substantial” health benefits to smokers who quit.
The senior author of the new report, Dr. Curt D. Furberg, a Wake Forest medical professor, said there were better ways to quit and called for removal of the drug from the market.
The smoking cessation drug Chantix has been linked to health risks by the Food & Drug Administration. Chantix was originally designed to assist adults who want to quit smoking, however studies show that Chantix may cause adverse side effects such as: suicidal thoughts, aggressive and erratic behavior. Adverse side effects and more extreme side effects may vary from person to person. With the latest study, cardiovascular side effects have now been linked to the drug’s usage.